This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

BioDelivery Sciences To Host Investor And Analyst Event And Webcast Friday, September 5 On BUNAVAIL™ Launch And Pipeline

RALEIGH, N.C.,
Aug. 27, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the company will be hosting an investor and analyst event and simultaneous webcast on
Friday, September 5, 2014. The event is scheduled for
12-2 pm ET in
New York City.

At this event, BDSI senior management will discuss the commercialization and launch plan for BUNAVAIL and provide updates on the BEMA
® Buprenorphine chronic pain and Clonidine Topical Gel programs. Nationally recognized addiction experts will discuss the growing epidemic of opioid dependence and the opportunity for BUNAVAIL.

A live webcast will be available on the company's website
www.bdsi.com.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA
®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's development strategy focuses on utilization of the FDA's 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.

BDSI's particular area of focus is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence.

Product Features:

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.